From 13 till 17 September 2024: HIGHLIGHTS FROM ESMO
Your direct line with Barcelona
The European Society of Medical Oncology (ESMO) 2024 brings together leading experts in the different fields of cancer from around the world. And this year they gather together in Barcelona, Spain. The MediMix team is also onsite, and will – together with your Belgian colleagues – keep you posted about the hottest topics as they happen. And, we dive into posters and hot topics with the experts as they are being presented.
Stay tuned, and get ready for an exciting and informative journey!
Latest Presidential highlights
Prof Domenica Lorusso, a gynaecological oncologist at Humanitas San Pio X, Milan, Italy, presented findings from the ENGOT-cx11/GOG-3047/KEYNOTE-A18 study during the presidential session.
The study evaluated the novel use of
Dr Elisa Agostinetto, medical oncologist at Institut Jules Bordet in Brussels, discussed with Dr Sofia Rivera, a radiation oncologist at Institut Gustave Roussy, France the outcomes of the HypoG-01 phase
Anal cancer, while relatively rare, has seen a rising incidence in recent years. Approximately 40% of patients with anal cancer will either experience relapse following primary treatment or develop de
Prof Dr Silke Gillessen, a medical oncologist at the EOC – Ospedale Regionale Bellinzona e Valli in Bellinzona, Switzerland, had the distinction of presenting the Late Breaking Abstract 1 as
Arguably one of the most anticipated presentations at ESMO 2024 featured the overall survival (OS) data of the pivotal phase III KEYNOTE-522 trial. Based on a convincing benefit in event-free
Latest Daily highlights
In this video, Prof Dr Els Van Nieuwenhuysen, gynaecological oncologist at the University Hospitals Leuven discusses four clinical trials that were presented during the proffered paper session on gynaecological cancer
In this video Dr Ana-Maria Bucalau discusses and comments on the data of some interesting studies that were presented at ESMO 2024 during the mini-oral session on upper digestive gastrointestinal
Dr Tom Van den Mooter and Dr Michiel Strijbos from ZAS Hospital in Antwerp shared key takeaways from ESMO 2024 regarding prostate cancer. They highlighted several trials, noting that some
Prof Mariana Brandão, medical oncologist at the Institut Jules Bordet in Brussels shares a selection of studies presented during the mini oral session of NSCLC that she had the honour
Prof Dr Hans Prenen, medical oncologist at the University Hospital Antwerp selected three abstracts from the mini oral session on lower GI tumours.
The OPERA trial, published in The Lancet
Dr Laure-Anne Teuwen, a medical oncologist at the University Hospital of Antwerp, provided insights from the second mini oral session on metastatic breast cancer at ESMO 2024.
Prof Dr Lore Decoster, a thoracic oncologist at UZ Brussels, provided an analysis of several abstracts presented during the second mini-oral session on NSCLC.
An updated analysis of the LAURA
Prof Bart Neyns, medical oncologist at UZ Brussel shares the key insights from the proffered paper session.
An updated pooled analysis from INMC with a three-year follow-up of patients treated
Professor Emmanuel Seront, medical oncologist at Cliniques Universitaires Saint-Luc in Belgium, provides a selection of highlights in urothelial and renal cancer from the mini oral session at ESMO.
There is
In this video, Prof Dr Marc Van den Eynde discusses and comments on the data of some interesting studies that were presented at ESMO 2024 during the proffered paper session
In this video, Dr Pieterjan Vanclooster discusses and comments on the data of some interesting studies presented at ESMO 2024 during the proffered paper session on head & neck cancer.
In this video, Prof Dr Hannelore Denys discusses and comments on the data of some exciting studies presented at ESMO 2024 during the Mini Oral session on gynaecological cancer.
Dr Dieter Stevens. thoracic oncologist at Ghent University Hospital discusses a selection of abstracts that were presented during the mini oral session on non-metastatic NSCLC.
Neoadjuvant and perioperative immunotherapy have
In this video, Dr Kevin Punie discusses and comments on the data of some exciting studies presented at ESMO 2024 during the Mini Oral session on metastatic breast cancer.
In this video, Prof Dr Karen Geboes discusses and comments on the data of some interesting studies that were presented at ESMO 2024 during the proffered paper session on upper
In this video, Dr Elisa Agostinetto discusses and comments on the data of some interesting studies presented at ESMO 2024 during the proffered paper session on early-stage breast cancer.
Dr Jérémy Blanc, medical oncologist in training at the Jules Bordet institute in Brussels discusses the key results of four clinical trials that were presented during the second proffered paper
In this video, Prof Dr Johan Vansteenkiste, a thoracic oncologist at the University Hospitals Leuven, discusses a selection of abstracts presented during the proffered paper session on non-metastatic lung cancer
Prof Dr Christine Gennigens, a medical oncologist at the University Hospital of CHU de Liège, focused on two studies presented during the mini oral session 2 on gynaecological cancers.
In this video, Dr Françoise Derouane, a medical oncologist at the University Hospitals Leuven, discusses a selection of abstracts presented during the proffered paper session on metastatic breast cancer during
In this video, Dr Francesco Sclafani, digestive oncologist at the Institut Jules Bordet,
summarises the key results of four clinical trials that were presented during the second proffered paper session
While ESMO did not feature any practice-changing presentations in the field of melanoma, it did provide interesting, long-term updates of pivotal clinical trials in addition to important insights from real-world
For his discussion of the mini-oral session on head and neck cancer at ESMO 2024, Dr Michael Saerens, medical oncologist at the University Hospital Ghent selected five interesting presentations.
The proffered paper session on metastatic non-small cell lung cancer (NSCLC) at ESMO 2024 focussed on three main topics: immune checkpoint inhibitor (ICI) combinations, the management of EGFR-mutant NSCLC after
Made possible with the financial support of our partners.
All videos are developed independently and are non-promotional.
